MedWatch

Saniona turns to rare diseases

Danish Saniona's candidate tesomet is already in phase II against a genetic disease causing obesity. According to CFO Thomas Feldthus, the candidate also has potential in another orphan drug indication.

Foto: Saniona/ PR

Within the next few years, Saniona's Mexican partner, Medix, can probably launch the Danish company's first drug.

And in the laboratories in Denmark, Saniona itself is working hard to develop its wholly owned candidate, tesomet, against type 2 diabetes.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier